Biocept's Lung Cancer Liquid Biopsy Test
Biocept has launched a lung cancer liquid biopsy test. The test uses proprietary technology to detect RET oncogene fusions from a simple blood draw. Genetic alterations in the RET and ROS1 genes were identified in patients with non-small cell lung cancer that have unique and pathologic features that may facilitate identification and enrichment strategies, the company said. The test comes after Biocept launched a blood-based test to detect the ROS1 biomarker in 2015.